The appointment comes as Braincure readies itself for clinical trials in Asia for the evaluation of a new approach to Alzheimers treatment
Online PR News – 06-November-2015 – Braincure-Biotech.com today announced that the company has engaged biotech industry veteran Mary Tien-tsan to serve on the executive team, as Research and Technology vice president, reporting to CEO Suhon Horng. Tien-tsan will work cross-functionally, driving business development, and growth strategies communication and investor relations. She will also serve as a Research and Technology spokesperson.
We are really excited that Mary is joining our executive team, said Mr. Horng. With more than two decades of experience in healthcare, and a focus on biotechnology and the life sciences, Mary has the expertise to work with teams across the company during this critical juncture.
Tien-tsan, a 20-year veteran of the healthcare industry, has worked with more than 100 life sciences, pharmaceutical and medical device and diagnostic companies across multiple disciplines. She has a particular focus on strategic planning and growth strategies for young companies and identifying opportunities to leverage success in visible ways as goals are met. Tien-tsan holds an undergraduate degree in medicine and a MBA in finance. She is a member of multiple industry organizations, and an invited speaker, author and blogger.
Braincure Biotech is preparing to evaluate an approach to Alzheimers treatment that has never before been studied in a clinically significant way, using an innovative device, said Tien-tsan. The driving vision behind our effort is to offer a potential new treatment in the Alzheimers space that has significant impact on disease progression. The opportunity to join the company at this time and help make this happen represents a professional challenge that I fully embrace.
About Braincure Biotech – http://www.braincure-biotech.com/